Evaxion Biotech A/S Completes ADS Ratio Change and Enhances Shareholder Value
COPENHAGEN, Denmark, Jan.22, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX), a leading clinical-stage TechBio company focusing on AI-Immunology powered vaccines, announced today the completion of its previously disclosed ADS Ratio Change.The change was made effective on January 22, 2024, and involves a shift from one American Depositary Share (ADS) representing one ordinary share to a new ADS Ratio of one ADS representing ten ordinary shares.
This decision by Evaxion Biotech aims to improve the company’s shareholder value and increase accessibility for investors interested in participating in the company’s growth potential.The new ADS Ratio will allow for a more efficient and streamlined trading process, enabling both existing and new shareholders to acquire a larger stake in the company through ADS transactions.
By implementing the ADS Ratio Change, Evaxion Biotech has demonstrated confidence in its future prospects and its commitment to optimizing shareholder returns.This move is expected to attract additional investment and enhance the liquidity of Evaxion’s shares in the market.
Evaxion Biotech had previously announced its plan to implement the ADS Ratio Change on January 8, 2024.With the completion of this change, the company has fulfilled its commitment within the expected timeframe, showcasing its ability to execute strategic decisions promptly.
Furthermore, Evaxion Biotech has also previously disclosed its share buyback program in Spar Nord Bank transactions.The company aims to repurchase shares worth up to DKK 300 million, as announced in company announcement no.8 in 2023.The share buyback program commenced on February 13, 2023, and reflects the company’s dedication to maximizing shareholder value by capitalizing on favorable market conditions.
As of the writing of this article, Evaxion Biotech’s share price stands at $0.67, resulting in a year-to-date performance of -8.22%. While the share price has faced some challenges recently, it is worth noting that the completion of the ADS Ratio Change and the share buyback program are strategic moves taken by the company to instill confidence in its long-term growth prospects.
In conclusion, Evaxion Biotech’s completion of the ADS Ratio Change highlights its commitment to enhancing shareholder value and optimizing trading efficiency.The successful implementation of this change, along with the ongoing share buyback program, reinforces the company’s dedication to creating long-term value for its shareholders.With its focus on developing AI-Immunology powered vaccines, Evaxion Biotech remains well-positioned in a rapidly growing market, and investors continue to closely watch its progress.
Comments